Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 232

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial

Joensuu, Heikki, Eriksson, Mikael, Sundby Hall, Kirsten, Reichardt, Annette, Hartmann, Jörg T., Pink, Daniel, Ramadori, Giuliano, Hohenberger, Peter, Al-Batran, Salah-Eddin, Schlemmer, Marcus, Bauer, Sebastian, Wardelmann, Eva, Nilsson, Bengt, Sihto, Harri, Bono, Petri, Kallio, Raija, Junnila, Jouni, Alvegård, Thor, Reichardt, Peter · 2016 · Journal of Clinical Oncology

Abstract

Purpose: Three years of adjuvant imatinib therapy are recommended for patients with GI stromal tumor (GIST) with high-risk features, according to survival findings in the Scandinavian Sarcoma Group XVIII/AIO (Arbeitsgemeinschaft Internistische Onkologie) trial. To investigate whether the survival benefits have persisted, we performed the second planned analysis of the trial. Patients and Methods: Eligible patients had macroscopically completely excised, KIT-positive GIST with a high risk of recurrence, as determined by using the modified National Institutes of Health criteria. After surgery, the patients were randomly assigned to receive imatinib for either 1 or 3 years. The primary objective was recurrence-free survival (RFS), and the secondary objectives included survival. Results: A total of 400 patients were entered onto this open-label study between February 4, 2004, and September 29, 2008. During a median follow-up of 90 months, 171 recurrences and 69 deaths were detected. Patients assigned to the 3-year group had longer RFS than those assigned to the 1- year group; 5-year RFS was 71.1% versus 52.3%, respectively (hazard ratio [HR], 0.60; 95% CI 0.44 to 0.81; P < .001), and survival was 91.9% versus 85.3% (HR, 0.60; 95% CI, 0.37 to 0.97; P = .036). Patients in the 3-year group survived longer in the subset with centrally confirmed GIST and without macroscopic metastases at study entry (93.4% v 86.8%; HR, 0.53; 95% CI, 0.30 to 0.93; P = .024). Similar numbers of cardiac events and second cancers were recorded in the groups. Conclusion: Three years of adjuvant imatinib therapy results in longer survival than 1 year of imatinib. High 5-year survival rates are achievable in patient populations with high-risk GIST.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.62.9170

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 232

Metadata

Authors
Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hartmann, J. T., Pink, D., Ramadori, G., Hohenberger, P., Al-Batran, S.-E., Schlemmer, M., Bauer, S., Wardelmann, E., Nilsson, B., Sihto, H., Bono, P., Kallio, R., Junnila, J., Alvegård, T., & Reichardt, P.
Venue
Journal of Clinical Oncology
Published
2016-01-20
Volume
34
Issue
3
Pages
244-250
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2115115592
Cited by
232
References
1
FWCI
21.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. https://app.cochat.ai/papers/10.1200/jco.2015.62.9170
The paper
Joensuu, H., Eriksson, M., Sundby Hall, K., Reichardt, A., Hartmann, J. T., Pink, D., Ramadori, G., Hohenberger, P., Al-Batran, S.-E., Schlemmer, M., Bauer, S., Wardelmann, E., Nilsson, B., Sihto, H., Bono, P., Kallio, R., Junnila, J., Alvegård, T., & Reichardt, P. (2016). Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.62.9170

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.